Management of hypertension during pregnancy: A meta-analysis

V. M. Jeevika 1, B. Hemalatha 1, K. S. Julega 1 and M. Mohankumar 2, *

1 Doctor of Pharmacy, Department of Pharmacy Practice, Arulmigu Kalasalingam College of Pharmacy, Anand Nagar, Krishnan Koil, Srivilliputhur, Tamil Nadu, India.
2 Assistant professor, Department of Pharmacy Practice, Arulmigu Kalasalingam College of Pharmacy, Anand Nagar, Krishnan Koil, Srivilliputhur, Tamil Nadu, India. 
 
Review
World Journal of Biology Pharmacy and Health Sciences, 2022, 12(03), 417-425.
Article DOI: 10.30574/wjbphs.2022.12.3.0267
Publication history: 
Received on 12 November 2022; revised on 25 December 2022; accepted on 28 December 2022
 
Abstract: 
Gestational hypertension, chronic hypertension, preeclampsia, and preeclampsia superimposed on pre-existing hypertension are the four categories into which the National High Blood Pressure Education Program of the NHLBI divides hypertensive disorders of pregnancy. Pregnant women with hypertension are at risk for death, renal failure, heart failure, hepatic rupture, cerebral edema, and cerebrovascular accidents. The foetuses of hypertension mothers are at risk for stillbirth, intrauterine growth restriction, and preterm birth difficulties after delivery due to maternal symptoms. When the diastolic pressure is greater than 90 to 110 mm Hg or the systolic pressure is greater than 140 to 170 mm Hg, most doctors start antihypertensive medication. A pre-pregnancy assessment for women with chronic hypertension should focus on end-organ damage, medication history, possible secondary causes of hypertension, and counselling on pregnancy's hazards. Women need to be monitored during their pregnancies, as well as during the intrapartum and postpartum periods.
 
Keywords: 
Preeclampsia (PE); Ambulatory blood pressure monitoring (ABPM); Hyperbaric index (HBI); Blood Pressure (BP); Renin-Angiotensin-Aldosterone System (RAAS)
 
Full text article in PDF: